Next-Generation Gynecological Cancer Diagnostics market to grow at a significant CAGR of 10.07% during 2020-2031. Next-Generation Gynecological Cancer Diagnostics market report by BIS Research provides deep market insight, industry analysis, trends & forecast to 2031 that will help your business to grow.
TOC - Global Extensive Stage Small Cell Lung Cancer Market.pdfBIS Research Inc.
Extensive stage small cell lung cancer is extremely aggressive sub-type of small cell lung cancer. Small cell lung itself is a sub-type of lung cancer which accounts for less than 20% cases. The treatment of extensive stage small cell lung cancer has been extremely challenging owing to poor survival rate of the patients.
The prevalence of extensive stage small lung cancer is estimated to increase in five of the seven major markets included in the study.
Global Viral and Non-Viral Vector Manufacturing Market.pdfBIS Research Inc.
The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.
Global Viral and Non-Viral Vector Manufacturing MarketBIS Research Inc.
The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.
Pediatric Genetic Testing Market - Global Analysis & ForeacstBIS Research Inc.
A large number of companies are emerging and competing to establish their dominance in the global pediatric genetic testing market. The companies in the market are undergoing significant activities to expand their market presence and establish their position in the global market.
Cell and Gene Therapy Market - Growth Analysis & TrendsBIS Research Inc.
The cell and gene therapy industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast year 2019-25
The somatic genetic testing market is expected to grow at a CAGR of 9.30% during the forecast period from 2020 to 2030. The market is projected to reach $16.79 billion by the end of 2030.
The Blood and Plasma Components Market size in 2020 was $39.58 billion and is expected to reach $66.47 billion in 2031, growing at a CAGR of 4.90% over the forecast period 2021-2031.
TOC - Global Extensive Stage Small Cell Lung Cancer Market.pdfBIS Research Inc.
Extensive stage small cell lung cancer is extremely aggressive sub-type of small cell lung cancer. Small cell lung itself is a sub-type of lung cancer which accounts for less than 20% cases. The treatment of extensive stage small cell lung cancer has been extremely challenging owing to poor survival rate of the patients.
The prevalence of extensive stage small lung cancer is estimated to increase in five of the seven major markets included in the study.
Global Viral and Non-Viral Vector Manufacturing Market.pdfBIS Research Inc.
The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.
Global Viral and Non-Viral Vector Manufacturing MarketBIS Research Inc.
The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.
Pediatric Genetic Testing Market - Global Analysis & ForeacstBIS Research Inc.
A large number of companies are emerging and competing to establish their dominance in the global pediatric genetic testing market. The companies in the market are undergoing significant activities to expand their market presence and establish their position in the global market.
Cell and Gene Therapy Market - Growth Analysis & TrendsBIS Research Inc.
The cell and gene therapy industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast year 2019-25
The somatic genetic testing market is expected to grow at a CAGR of 9.30% during the forecast period from 2020 to 2030. The market is projected to reach $16.79 billion by the end of 2030.
The Blood and Plasma Components Market size in 2020 was $39.58 billion and is expected to reach $66.47 billion in 2031, growing at a CAGR of 4.90% over the forecast period 2021-2031.
The single cell RNA sequencing market is anticipated to reach a value of $2,931.3 million in 2031 from $386.7 million in 2020, witnessing a compound annual growth rate (CAGR) of 17.08% during the forecast period 2021-2031.
The global cell-free DNA isolation and extraction market was valued at $169.9 million in 2020 and is expected to reach $735.1 million by 2031, witnessing a CAGR of 14.19% during the forecast period 2021-2031.
The global cell-free DNA isolation and extraction market was valued at $169.9 million in 2020 and is expected to reach $735.1 million by 2031, witnessing a CAGR of 14.19% during the forecast period 2021-2031
The global aseptic pharma processing market was valued to be $10,633.3 million in 2020 and is expected to reach $24,364.0 million by 2031, witnessing a CAGR of 7.90% during the forecast period 2021-2031.
Aseptic Pharma Processing Market - Global and Regional AnalysisBIS Research Inc.
The global aseptic pharma processing market was valued to be $10,633.3 million in 2020 and is expected to reach $24,364.0 million by 2031, witnessing a CAGR of 7.90% during the forecast period 2021-2031.
The global oncology precision medicine market was valued at $45,174.2 million in 2020 and is expected to reach $1,28,891.6 million by 2031, growing at a CAGR of 10.05% during the forecast period 2021-2031.
Precision cardiology industry to be one of the most rapidly evolving and dynamic markets and is predicted to grow at a CAGR of 12.90% over the forecast period of 2021-2031.
The Europe infectious disease diagnostics market was valued at $1,394.3 million in 2020 and is expected to reach $7,900.4 million by 2031, witnessing a CAGR of 16.48% during the forecast period 2021-2031.
Molecular Oncology Diagnostics Market Analysis and Forecast, 2022-2032BIS Research Inc.
The global molecular oncology diagnostics market was valued at $3,620.6 million in 2021 and is anticipated to reach $12,130.5 million by 2032, witnessing a CAGR of 11.43% during the forecast period 2022-2032.
Table of Content - Global Prostate Cancer Testing Market.pdfBIS Research Inc.
The global prostate cancer testing market was valued at $5,246.9 million in 2021, and it is expected to reach $21,306.9 million by 2032, growing at a CAGR of 13.68% during the forecast period 2022-2032.
Our healthcare experts have found PD-1/PD-L1 immunotherapy to be one of the most rapidly adopted therapies, and the global market for PD-1/PD-L1 immunotherapy is predicted to grow at a CAGR of 10.72% over the forecast period of 2020-2030.
U.S. Hereditary Genetic Testing Market Analysis and Forecast, 2022-2032BIS Research Inc.
The U.S. hereditary genetic testing market was valued at $7.57 billion in 2021 and is expected to grow with a CAGR of 13.09% and reach $29.28 billion by 2032.
The global biomaterials market was valued at $122.92 billion in 2020 and is expected to reach $725.88 billion by 2031, growing at a CAGR of 17.98% between 2021 and 2031.
The global CRISPR gene editing market was valued at $1,088.6 million in 2020, and it is expected to reach $18,856.6 million by 2031, registering a CAGR of 29.60% during the forecast period.
The In-silico drug discovery market is predicted to grow from $2,129.8 million in 2020 to $6,515.3 million in 2031 and is expected to grow with a CAGR of 10.52% during the forecast period 2021-2031.
AI-Enabled Imaging Solutions Market - A Global Market Report by BIS ResearchBIS Research Inc.
The global AI-enabled medical imaging solutions market was valued at $1,854.5 million in 2022 and is anticipated to reach $18,356.5 million by 2032, witnessing a CAGR of 25.76% during the forecast period 2022-2032. you can get more info to visit this link..
https://bisresearch.com/industry-report/global-ai-enabled-medical-imaging-solutions-market.html
This document provides an overview of the global digital biomarkers market with a focus on system components, types, applications, end users, and regional analysis. It discusses the current state and types of digital biomarkers as well as the ecosystem comprising wearable devices, implantables, mobile applications, and data integration software. The document also analyzes the impact of COVID-19 on digital biomarkers adoption, key industry trends, opportunity assessment, and competitive landscape. Regional sections provide market estimations for North America and Europe with country-level analyses of leading markets like the U.S., Canada, Germany, France, and others.
Laboratory Informatics Market Analysis and Forecast, 2022-2032BIS Research Inc.
The global laboratory informatics market is anticipated to reach $12,677.0 million by 2032, witnessing a CAGR of 10.27% during the forecast period 2022-2032.
The global pharmacogenomics services market is projected to reach $9,346.8 million by 2031 from $5,060.0 million in 2020, at a CAGR of 5.71% during the forecast period 2021-2031.
Webinar Presentation Syndromic Testing – A New Take on Diagnosing Infectious ...BIS Research Inc.
The document summarizes a webinar on syndromic testing for diagnosing infectious diseases. The webinar featured several speakers who discussed topics like: how syndromic testing can provide faster results and reduce antibiotic use compared to traditional testing; applications of metagenomics next-generation sequencing (mNGS) in clinical diagnostics and its benefits; key trends in the syndromic testing market like high growth rates and the dominance of respiratory disease testing currently. The global syndromic testing market is expected to grow from $1.28 billion in 2022 to $3.25 billion in 2033, driven by factors like rising infectious disease incidence and the need for early diagnosis.
The global sustainable steel market is projected to reach $795.8 billion by 2031 from $327.3 billion in 2021, growing at a CAGR of 8.97% during the forecast period 2022-2031. The growth in the global sustainable steel market is expected to be driven by stringent government regulations, carbon neutrality targets, energy and cost efficiency owing to the use of recycled steel, and a significant increase in steel demand with the scarcity of raw materials and energy.
More Related Content
Similar to Next Generation Gynecological Cancer Diagnostics Market.pdf
The single cell RNA sequencing market is anticipated to reach a value of $2,931.3 million in 2031 from $386.7 million in 2020, witnessing a compound annual growth rate (CAGR) of 17.08% during the forecast period 2021-2031.
The global cell-free DNA isolation and extraction market was valued at $169.9 million in 2020 and is expected to reach $735.1 million by 2031, witnessing a CAGR of 14.19% during the forecast period 2021-2031.
The global cell-free DNA isolation and extraction market was valued at $169.9 million in 2020 and is expected to reach $735.1 million by 2031, witnessing a CAGR of 14.19% during the forecast period 2021-2031
The global aseptic pharma processing market was valued to be $10,633.3 million in 2020 and is expected to reach $24,364.0 million by 2031, witnessing a CAGR of 7.90% during the forecast period 2021-2031.
Aseptic Pharma Processing Market - Global and Regional AnalysisBIS Research Inc.
The global aseptic pharma processing market was valued to be $10,633.3 million in 2020 and is expected to reach $24,364.0 million by 2031, witnessing a CAGR of 7.90% during the forecast period 2021-2031.
The global oncology precision medicine market was valued at $45,174.2 million in 2020 and is expected to reach $1,28,891.6 million by 2031, growing at a CAGR of 10.05% during the forecast period 2021-2031.
Precision cardiology industry to be one of the most rapidly evolving and dynamic markets and is predicted to grow at a CAGR of 12.90% over the forecast period of 2021-2031.
The Europe infectious disease diagnostics market was valued at $1,394.3 million in 2020 and is expected to reach $7,900.4 million by 2031, witnessing a CAGR of 16.48% during the forecast period 2021-2031.
Molecular Oncology Diagnostics Market Analysis and Forecast, 2022-2032BIS Research Inc.
The global molecular oncology diagnostics market was valued at $3,620.6 million in 2021 and is anticipated to reach $12,130.5 million by 2032, witnessing a CAGR of 11.43% during the forecast period 2022-2032.
Table of Content - Global Prostate Cancer Testing Market.pdfBIS Research Inc.
The global prostate cancer testing market was valued at $5,246.9 million in 2021, and it is expected to reach $21,306.9 million by 2032, growing at a CAGR of 13.68% during the forecast period 2022-2032.
Our healthcare experts have found PD-1/PD-L1 immunotherapy to be one of the most rapidly adopted therapies, and the global market for PD-1/PD-L1 immunotherapy is predicted to grow at a CAGR of 10.72% over the forecast period of 2020-2030.
U.S. Hereditary Genetic Testing Market Analysis and Forecast, 2022-2032BIS Research Inc.
The U.S. hereditary genetic testing market was valued at $7.57 billion in 2021 and is expected to grow with a CAGR of 13.09% and reach $29.28 billion by 2032.
The global biomaterials market was valued at $122.92 billion in 2020 and is expected to reach $725.88 billion by 2031, growing at a CAGR of 17.98% between 2021 and 2031.
The global CRISPR gene editing market was valued at $1,088.6 million in 2020, and it is expected to reach $18,856.6 million by 2031, registering a CAGR of 29.60% during the forecast period.
The In-silico drug discovery market is predicted to grow from $2,129.8 million in 2020 to $6,515.3 million in 2031 and is expected to grow with a CAGR of 10.52% during the forecast period 2021-2031.
AI-Enabled Imaging Solutions Market - A Global Market Report by BIS ResearchBIS Research Inc.
The global AI-enabled medical imaging solutions market was valued at $1,854.5 million in 2022 and is anticipated to reach $18,356.5 million by 2032, witnessing a CAGR of 25.76% during the forecast period 2022-2032. you can get more info to visit this link..
https://bisresearch.com/industry-report/global-ai-enabled-medical-imaging-solutions-market.html
This document provides an overview of the global digital biomarkers market with a focus on system components, types, applications, end users, and regional analysis. It discusses the current state and types of digital biomarkers as well as the ecosystem comprising wearable devices, implantables, mobile applications, and data integration software. The document also analyzes the impact of COVID-19 on digital biomarkers adoption, key industry trends, opportunity assessment, and competitive landscape. Regional sections provide market estimations for North America and Europe with country-level analyses of leading markets like the U.S., Canada, Germany, France, and others.
Laboratory Informatics Market Analysis and Forecast, 2022-2032BIS Research Inc.
The global laboratory informatics market is anticipated to reach $12,677.0 million by 2032, witnessing a CAGR of 10.27% during the forecast period 2022-2032.
The global pharmacogenomics services market is projected to reach $9,346.8 million by 2031 from $5,060.0 million in 2020, at a CAGR of 5.71% during the forecast period 2021-2031.
Similar to Next Generation Gynecological Cancer Diagnostics Market.pdf (20)
Webinar Presentation Syndromic Testing – A New Take on Diagnosing Infectious ...BIS Research Inc.
The document summarizes a webinar on syndromic testing for diagnosing infectious diseases. The webinar featured several speakers who discussed topics like: how syndromic testing can provide faster results and reduce antibiotic use compared to traditional testing; applications of metagenomics next-generation sequencing (mNGS) in clinical diagnostics and its benefits; key trends in the syndromic testing market like high growth rates and the dominance of respiratory disease testing currently. The global syndromic testing market is expected to grow from $1.28 billion in 2022 to $3.25 billion in 2033, driven by factors like rising infectious disease incidence and the need for early diagnosis.
The global sustainable steel market is projected to reach $795.8 billion by 2031 from $327.3 billion in 2021, growing at a CAGR of 8.97% during the forecast period 2022-2031. The growth in the global sustainable steel market is expected to be driven by stringent government regulations, carbon neutrality targets, energy and cost efficiency owing to the use of recycled steel, and a significant increase in steel demand with the scarcity of raw materials and energy.
Cybersecurity in Automotive Connected Vehicles and Growing Security Vulnerabi...BIS Research Inc.
• Agenda:
o To evaluate various security vulnerabilities in connected vehicles.
o To analyze the initiatives taken and regulations implemented to address security vulnerabilities.
o To analyze the various types of cybersecurity solutions being developed or offered for the security of connected vehicles.
o To evaluate the major players in the ecosystem.
Report Preview is available at: https://bisresearch.com/industry-report/global-automotive-cybersecurity-market.html
BIS Research conducted a webinar on Carbon Neutral Data Center PracticesBIS Research Inc.
Agenda:
To evaluate various emerging trends in Data center industry.
To analyze the initiatives taken and regulations implemented to increase sustainable practices.
To analyze the various types of technologies currently deployed.
To evaluate the major players in the ecosystem.
Speaker Profiles:
Name: JD Enright, Sr.
Designation: Chief Operating Officer
Company: TMGcore Inc.
Experienced and dedicated business professional with 29 years working with DOD, Multinational Private and Public sector organizations. Primary focus on developing and executing Strategic Step-Up Growth initiatives in Emerging Markets, and Technologies. Specialized leadership in developing improved business operations to include Financial and Operational efficiencies. Implementation of next generation HPC Platforms, Global Blockchain Development Strategies, Biotechnology, Viral Cell and Gene Therapies and Market Intelligence Assimilation for public applications.
Webinar by BIS Research on Precision Oncology BiomarkersBIS Research Inc.
Precision oncology biomarkers are essential tools for tailoring cancer treatment to individual patients, as they provide insights into tumor biology and guide the selection of targeted therapies.
BIS conducted a deep intelligence webinar on the state-of-the-art technologies and emerging strategies used through the precision oncology biomarkers.
Direct-to-Customer Wellness | A Webinar on the Growing Need for Personalized ...BIS Research Inc.
Direct-to-consumer (DTC) wellness testing industry witnessed a strong emphasis on consumer health and wellness, instigating industry stakeholders to discover new revenue streams.
As a leading market intelligence firm, BIS Research strives to stay on top of the latest emerging trends in the healthcare sector, among several other industry verticals. In the bid to do the same, BIS is conducting a deep intelligence webinar on the increasing focus of DTC wellness programs in the healthcare sector.
Read Related Reports Overview at:
https://bisresearch.com/industry-report/global-direct-to-consumer-genetic-testing-market.html
https://bisresearch.com/industry-report/us-dtc-wellness-testing-market.html
Emerging Battery Chemistries | Reimagining EVs Beyond Conventional Li-Ion Bat...BIS Research Inc.
The efficiency of the battery system in any electric vehicle (EV) determines its cost and vehicle performance. Challenges, such as range anxiety and charging time, have been a hindrance to increasing EV sales.
As a leading market intelligence firm, BIS Research strives to stay on top of the latest emerging technologies in the mobility sector, among several other industry verticals.
In the bid to do the same, BIS is conducting a deep intelligence webinar on the current paradigm shift happening for battery technologies in electric vehicles.
Here are all the details:
Webinar Topic: Emerging Battery Chemistries | Reimagining EVs Beyond Conventional Li-Ion Batteries
Webinar on AI in Medical Diagnosis with Emerging TechnologiesBIS Research Inc.
Artificial Intelligence (AI) is a rapidly growing field that has the potential to revolutionize the way medical diagnosis is performed. AI systems use advanced algorithms to analyze large amounts of data, such as medical images, patient histories, and lab results, to identify patterns and make predictions about patient outcomes.
In medical diagnosis, AI can be used in a variety of ways, including medical imaging, disease diagnosis, personalized treatment planning, and early disease detection. By leveraging the power of AI, healthcare providers can make faster and more accurate diagnoses, resulting in better patient outcomes.
Agenda:
The main agenda of this webinar is to understand and explore the following:
• Policy implications related to AI and digital transformation in healthcare.
• Initiatives taken and regulations implemented to address cybersecurity concerns.
• Major factors driving and hindering the growth of AI in medical devices diagnosis.
• Major players in the ecosystem
The global demand for achieving the net zero emission target by 2050 has pushed governments all over to adapt and adopt advanced carbon removal technologies to go carbon negative.
It is, indeed, an important topic of discussion, because a carbon free environment is the need of the hour to save our planet. And, therefore, BIS Research is glad to announce its upcoming webinar on this particular subject.
Agenda:
The main agenda of this webinar is to understand and explore the following:
• Primary sources of carbon emissions and associated environmental issues
• Carbon dioxide removal – key technology and adoption scenario
• Carbon dioxide removal (CDR): trends and key market developments
• Carbon dioxide removal as a credible solution
• Conclusion and future outlook
Webinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy DevelopmentBIS Research Inc.
Agenda of the Webinar:
Cell and Gene Therapy Biomanufacturing Market: Trends and Key Developments
Awaited Technologies in the Cell and Gene Therapy Development
Regulatory Scenario – GMP/cGMP Guidelines
Biomanufacturing 4.0 - Adoption Scenario
Conclusion and Future Outlook
Sub-Orbital Testing Services Market Future Growth and Business Opportunities ...BIS Research Inc.
Sub-orbital platforms are increasing access to the near space-like environment for end users such as government agencies, research institutions, and commercial players.
The competitive landscape of the sub-orbital testing services market consists of several organic and inorganic strategies followed by the key players to increase their market share.
The space industry is continuously innovating and developing advanced technologies with the objective of enhancing space capabilities. The industry is gearing up to develop vehicles that entail a major feature, i.e., reusability.
Request for the sample of the report at: https://bisresearch.com/requestsample?id=1442&type=download
TOC - Global Military Robotic and Autonomous Systems (RAS) Market.pdfBIS Research Inc.
The robotic and autonomous system (RAS) is a multidisciplinary scientific and technological domain for implementing complex systems with cognitive capabilities.
RAS in military is being rigorously introduced and used in combat training. This has boosted the capabilities of armed units and subunits. The advent of artificial intelligence (AI) and its integration with military RAS has the potential to change future warfare.
Growing demand to increase warfighter lethality and remove soldiers from dangerous situations is propelling the global military RAS market.
Request for the sample of the report at: https://bisresearch.com/requestsample?id=1442&type=download
UAV Propulsion System Market Analysis, Statistics, Regional, and Forecast to ...BIS Research Inc.
UAV propulsion system manufacturers have also been inclined to counter the environment and other government regulations by developing sustainable propulsion, i.e., steps toward fossil-free aviation fuels and ion propulsion are a few of such significant innovations.
UAVs can be powered by a variety of different types of engines, including piston engines, turbine engines, Wankel engines, and electric and solar-powered engines.
The global UAV propulsion system market has witnessed a high growth rate in the last five to six years owing to its widespread applications across various industries, which were further bolstered by the COVID-19 pandemic.
Publication of BIS Research on UAV Propulsion System market has some great insights for UAV Propulsion Systems. Get free sample here: https://bisresearch.com/requestsample?id=1443&type=download
Fleet Management Market Trends, Key Players, Industry Analysis and Forecast 2...BIS Research Inc.
A fleet management system, which includes hardware, software and service, has the ability to make decisions for fleet managers and fleet businesses easily.
The ongoing research and development activities in this market are experiencing product launches of fleet management system for fleet owners, fleet managers, or businesses that utilize fleet management on a daily basis.
BIS Research has a new publication on Fleet Management, view free sample here : https://bisresearch.com/requestsample?id=1444&type=download
Agenda:
The main agenda of this webinar is to understand and explore the following:
• LoRaWAN adoption in agricultural applications as well as understanding the trends and key market developments.
• The significance of LoRaWAN in the field of IoT
• A comparative analysis between LoRaWAN and other IoT networks in terms of technology and capabilities.
• The impact of LoRaWAN on the operations of the agriculture industry and common use cases.
• The impact of the implementation of LoRaWAN technology on stakeholders in the agriculture ecosystem.
• The potential challenges that LoRaWAN might face in the future.
• The competitiveness of the market for LoRaWAN technology.
Augmented Reality in Agriculture Analysis and Statistics from 2022-2027BIS Research Inc.
AR depicts superimposing visual, audio, or other sensory data onto the physical world to improve one's experience. It is one of the most popular technological trends in today’s times. AR images can be displayed on a variety of devices, including eyeglasses and goggles, headsets, and heads-up displays such as helmet visors. As more smartphones, tablets, and other handheld devices that support AR are becoming available globally, the most popular way to use AR is on these devices in a variety of apps and games.
Although AR is used to visually communicate information, it is the integration of AR with other technologies that make it possible to adapt to precision farming and visual-based operations. Hence, farmers can utilize AR in combination with other technologies such as artificial intelligence (AI), big data, and the Internet of Things (IoT) to manage the rising food demand.
Get Augmented Reality in Agriculture report overview at: https://bisresearch.com/industry-report/ar-agriculture-market.html
Smart Harvest Market Generated Opportunities, Future Scope 2022-2027BIS Research Inc.
The growth in the global smart harvest market is expected to be driven by increasing smart farming practices among farmers, labor shortage, and growing government support for promoting the use of smart tech in the agriculture industry. Supported by government policies and technological developments, farmers and growers across the globe are expected to increase the implementation of smart harvest technologies. Moreover, the smart harvest market is witnessing several upcoming trends and opportunities, further propelling growth in the industry.
Get the PDF document on the technical aspects of Smart Harvest Market at: https://bisresearch.com/requestsample?id=1386&type=download
Precision Pest Management Market Leading Players, Development and Demand Fore...BIS Research Inc.
While farmers are losing crops due to pests, they have pressure to increase food production to feed the growing world population.
Precision pest management (PPM) is very important to avoid destruction caused by pests and to increase productivity. PPM helps to detect pests early with the help of crop monitoring so they can be controlled early to avoid further losses. The availability of advanced technologies and equipment has made agriculture automation more prevalent in developed countries.
To know more about the in-depth insights on precision pest management market, get PDF document: https://bisresearch.com/requestsample?id=1404&type=download
Agriculture Drones and Robots Market Growth Opportunity, Trends, Demand Analy...BIS Research Inc.
Agriculture drones and robots offer multiple benefits over conventional farming equipment, which is another factor driving the demand for these products in the agriculture industry. The adoption of agriculture drones and robots in commercial farms offers huge cost-saving opportunities.
Request for the Sample of the Report at: https://bisresearch.com/requestsample?id=1425&type=download
Next-Generation Automotive Lighting Industry to See Significant Growth During...BIS Research Inc.
Since the inception of automotive vehicles amongst the masses, automotive lighting has witnessed significant growth owing to the growing safety apprehensions revolving around vehicles.
The rapid technical progress in the automotive lighting field shows that basic light sources based on incandescent and gas-release bulbs have shifted to modern-day technologies such as light-emitting diodes (LEDs), laser technology, and organic light-emitting diodes (OLEDs).
Get the Sample of the Report containing the information on various technical aspects at: https://bisresearch.com/requestsample?id=1435&type=download
Can Allopathy and Homeopathy Be Used Together in India.pdfDharma Homoeopathy
This article explores the potential for combining allopathy and homeopathy in India, examining the benefits, challenges, and the emerging field of integrative medicine.
MBC Support Group for Black Women – Insights in Genetic Testing.pdfbkling
Christina Spears, breast cancer genetic counselor at the Ohio State University Comprehensive Cancer Center, joined us for the MBC Support Group for Black Women to discuss the importance of genetic testing in communities of color and answer pressing questions.
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
This particular slides consist of- what is Pneumothorax,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is a summary of Pneumothorax:
Pneumothorax, also known as a collapsed lung, is a condition that occurs when air leaks into the space between the lung and chest wall. This air buildup puts pressure on the lung, preventing it from expanding fully when you breathe. A pneumothorax can cause a complete or partial collapse of the lung.
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareDr. David Greene Arizona
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
Healthy Eating Habits:
Understanding Nutrition Labels: Teaches how to read and interpret food labels, focusing on serving sizes, calorie intake, and nutrients to limit or include.
Tips for Healthy Eating: Offers practical advice such as incorporating a variety of foods, practicing moderation, staying hydrated, and eating mindfully.
Benefits of Regular Exercise:
Physical Benefits: Discusses how exercise aids in weight management, muscle and bone health, cardiovascular health, and flexibility.
Mental Benefits: Explains the psychological advantages, including stress reduction, improved mood, and better sleep.
Tips for Staying Active:
Encourages consistency, variety in exercises, setting realistic goals, and finding enjoyable activities to maintain motivation.
Maintaining a Balanced Lifestyle:
Integrating Nutrition and Exercise: Suggests meal planning and incorporating physical activity into daily routines.
Monitoring Progress: Recommends tracking food intake and exercise, regular health check-ups, and provides tips for achieving balance, such as getting sufficient sleep, managing stress, and staying socially active.
At Apollo Hospital, Lucknow, U.P., we provide specialized care for children experiencing dehydration and other symptoms. We also offer NICU & PICU Ambulance Facility Services. Consult our expert today for the best pediatric emergency care.
For More Details:
Map: https://cutt.ly/BwCeflYo
Name: Apollo Hospital
Address: Singar Nagar, LDA Colony, Lucknow, Uttar Pradesh 226012
Phone: 08429021957
Opening Hours: 24X7
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in CardiologyR3 Stem Cell
Dr. David Greene, founder and CEO of R3 Stem Cell, is at the forefront of groundbreaking research in the field of cardiology, focusing on the transformative potential of stem cell therapy. His latest work emphasizes innovative approaches to treating heart disease, aiming to repair damaged heart tissue and improve heart function through the use of advanced stem cell techniques. This research promises not only to enhance the quality of life for patients with chronic heart conditions but also to pave the way for new, more effective treatments. Dr. Greene's work is notable for its focus on safety, efficacy, and the potential to significantly reduce the need for invasive surgeries and long-term medication, positioning stem cell therapy as a key player in the future of cardiac care.
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...rightmanforbloodline
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
Feeding plate for a newborn with Cleft Palate.pptxSatvikaPrasad
A feeding plate is a prosthetic device used for newborns with a cleft palate to assist in feeding and improve nutrition intake. From a prosthodontic perspective, this plate acts as a barrier between the oral and nasal cavities, facilitating effective sucking and swallowing by providing a more normal anatomical structure. It helps to prevent milk from entering the nasal passage, thereby reducing the risk of aspiration and enhancing the infant's ability to feed efficiently. The feeding plate also aids in the development of the oral muscles and can contribute to better growth and weight gain. Its custom fabrication and proper fitting by a prosthodontist are crucial for ensuring comfort and functionality, as well as for minimizing potential complications. Early intervention with a feeding plate can significantly improve the quality of life for both the infant and the parents.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)bkling
Your mindset is the way you make sense of the world around you. This lens influences the way you think, the way you feel, and how you might behave in certain situations. Let's talk about mindset myths that can get us into trouble and ways to cultivate a mindset to support your cancer survivorship in authentic ways. Let’s Talk About It!
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
Next Generation Gynecological Cancer Diagnostics Market.pdf
1. 1
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
res
https://www.freepik.com/premium-vector/dna-strand-molecular-structure-genetic-engineering-laboratory-research_4927901.htm
Focus on Technology, Product Type, End
User, and Country Analysis
Analysis and Forecast: 2020-2031
February 2022
Next-Generation
Gynecological Cancer
Diagnostics Market -
A Global Market and
Regional Analysis
Table of Content
3. 3
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Table of Content
1. Definition.................................................................................. 27
1.1 Inclusion and Exclusion Criteria ....................................................................27
1.1.1 Inclusions.....................................................................................................27
1.1.2 Exclusions ...................................................................................................27
2. Research Scope....................................................................... 28
2.1 Key Questions Answered in the Report ........................................................29
3. Research Methodology............................................................. 30
3.1 Global Next-Generation Gynecological Cancer Diagnostics Market:
Research Methodology ...................................................................................30
3.2 Data Sources....................................................................................................31
3.2.1 Primary Data Sources .................................................................................31
3.2.2 Secondary Data Sources ............................................................................32
3.3 Market Estimation Model.................................................................................32
3.4 Criteria for Company Profiling........................................................................34
4. Market...................................................................................... 35
4.1 Introduction......................................................................................................36
4.2 Molecular Profiling and Techniques ..............................................................37
4.3 Role of Molecular Diagnostics in Gynecological Cancers...........................39
4.4 Diagnostic Technologies and Regulatory Landmarks Timeline in
Gynecological Cancers ...................................................................................40
4.5 Emerging Molecular Testing in Gynecological Cancer ................................41
4.6 Current Market Size and Growth Potential, $Million, 2021-2031..................45
5. Role of Biomarkers in Gynecological Cancer............................. 47
5.1 Introduction......................................................................................................47
5.2 Predictive Molecular Testing in Gynecological Cancer ...............................48
5.3 Companion Diagnostics (CDx) .......................................................................49
6. COVID-19 Impact on Global Next-Generation Gynecological
Cancer Diagnostics Market ...................................................... 51
6.1 Impact on Supply Chain and Operations.......................................................51
4. 4
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
6.2 COVID-19 Impact: Global Next-Generation Gynecological Cancer
Diagnostics Market..........................................................................................53
6.3 Pre- and Post-COVID-19 Impact Assessment ...............................................54
7. Market Dynamics...................................................................... 55
7.1 Overview...........................................................................................................55
7.2 Impact Analysis ...............................................................................................56
7.3 Market Drivers..................................................................................................56
7.3.1 Subsequent Decline in Next-Generation Sequencing (NGS) Cost..........56
7.3.2 Increased Recommendations from Government Organizations and
Scientific Societies......................................................................................57
7.3.3 Increased Awareness and Shift Toward Personalized Medicine.............57
7.4 Market Restraints.............................................................................................59
7.4.1 Limited Food and Drug Administration (FDA) Approved Next-
Generation Sequencing (NGS) tests..........................................................59
7.4.2 Complexities Involved with Overall Next-Generation Sequencing
(NGS) Process and Result Interpretation ..................................................59
7.4.3 Reimbursement Challenges Across the Countries ..................................61
7.5 Market Opportunities.......................................................................................61
7.5.1 Increased Market Investments and Government Funded Projects.........61
7.5.2 Next-Generation Sequencing (NGS) Acceptance by Emerging
Nations .........................................................................................................62
8. Industry Insights....................................................................... 63
8.1 Overview...........................................................................................................63
8.2 Legal Requirements and Framework in the U.S............................................63
8.2.1 FDA Regulation............................................................................................63
8.2.2 CMS Regulation...........................................................................................64
8.3 Legal Requirements and Framework in Europe............................................65
8.4 Legal Requirements and Framework in Asia-Pacific....................................66
8.4.1 China ............................................................................................................66
8.4.2 Japan............................................................................................................66
8.5 Reimbursement Scenario................................................................................67
5. 5
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
8.6 Funding Scenario ............................................................................................70
9. Market Segmentation ............................................................... 71
9.1 Global Next-Generation Gynecological Cancer Diagnostics Market (by
Technology), $Million, 2020-2031...................................................................72
9.1.1 Overview ......................................................................................................72
9.1.1.1 Polymerase Chain Reaction (PCR) ..................................................................73
9.1.1.1.1 by Value ................................................................................................................... 73
9.1.1.1.2 by Volume ................................................................................................................ 74
9.1.1.2 Next-Generation Sequencing (NGS) ................................................................75
9.1.1.2.1 by Value ................................................................................................................... 76
9.1.1.2.2 by Volume ................................................................................................................ 76
9.1.1.2.3 Broad Panels............................................................................................................ 77
9.1.1.2.3.1 by Value............................................................................................................ 77
9.1.1.2.3.2 by Volume......................................................................................................... 78
9.1.1.2.4 Targeted Gene Panels............................................................................................. 79
9.1.1.2.4.1 by Value............................................................................................................ 79
9.1.1.2.4.2 by Volume......................................................................................................... 80
9.1.1.2.5 Single Gene Panels ................................................................................................. 80
9.1.1.2.5.1 by Value............................................................................................................ 80
9.1.1.2.5.2 by Volume......................................................................................................... 81
9.1.1.3 Other Technologies..........................................................................................82
9.1.1.3.1 by Value ................................................................................................................... 82
9.1.1.3.2 by Volume ................................................................................................................ 83
10. Global Next-Generation Gynecological Cancer Diagnostics
Market (by Product Type), $Million, 2020-2031.......................... 84
10.1 Overview...........................................................................................................84
10.2 Services............................................................................................................85
10.3 Products ...........................................................................................................86
11. Global Next-Generation Gynecological Cancer Diagnostics
Market (by Indication), $Million, 2020-2031 ............................... 88
6. 6
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
11.1 Overview...........................................................................................................88
11.2 Ovarian Cancer ................................................................................................89
11.3 Cervical Cancer................................................................................................90
11.4 Uterine Cancer .................................................................................................91
12. Global Next-Generation Gynecological Cancer Diagnostics
Market (by End User), $Million, 2020-2031 ................................ 92
12.1 Overview...........................................................................................................92
12.2 Academic and Research Institutes ................................................................93
12.3 Hospitals and Ambulatory Centers................................................................94
12.4 Diagnostic Laboratories..................................................................................95
12.5 Other End Users ..............................................................................................96
13. Global Next-Generation Gynecological Cancer Diagnostics
Market (by Region), $Million, 2020-2031.................................... 97
13.1 Overview...........................................................................................................97
13.2 North America................................................................................................100
13.2.1 U.S. .............................................................................................................103
13.2.2 Canada .......................................................................................................104
13.3 Europe ............................................................................................................106
13.3.1 Germany.....................................................................................................109
13.3.2 U.K. .............................................................................................................110
13.3.3 France.........................................................................................................111
13.3.4 Italy .............................................................................................................112
13.3.5 Spain...........................................................................................................114
13.3.6 Netherlands................................................................................................115
13.3.7 Rest-of-Europe...........................................................................................116
13.4 Asia-Pacific ....................................................................................................117
13.4.1 China ..........................................................................................................119
13.4.2 Japan..........................................................................................................121
13.4.3 India............................................................................................................122
13.4.4 Australia.....................................................................................................123
7. 7
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
13.4.5 South Korea ...............................................................................................124
13.4.6 Rest-of-Asia-Pacific...................................................................................125
13.5 Latin America.................................................................................................126
13.5.1 Brazil...........................................................................................................129
13.5.2 Mexico ........................................................................................................130
13.5.3 Rest-of-Latin America ...............................................................................131
13.6 Rest-of-the-World (RoW)...............................................................................132
14. Competitive Landscape and Company Profiles........................ 133
14.1 Competitive Landscape ................................................................................134
14.2 Regulatory and Legal Activities ...................................................................134
14.3 Synergistic Activities ....................................................................................135
14.4 Mergers and Acquisitions.............................................................................136
14.5 Product Launches .........................................................................................137
14.6 Business Expansions....................................................................................138
14.7 Market Share Analysis, by Service Providers, 2020 ...................................139
14.8 Market Share Analysis, by Product Manufacturers, 2020 ..........................141
14.9 Growth Share Analysis, by Company, 2019-2020.......................................142
14.9.1 Growth Share Analysis, by Service Providers, 2019-2020.....................142
14.9.2 Growth Share Analysis, by Product Manufacturers, 2019-2020............143
15. Company Profiles ................................................................... 145
15.1 Overview.........................................................................................................145
15.2 Agilent Technologies, Inc. ............................................................................146
15.2.1 Company Overview ...................................................................................146
15.2.2 Role of Agilent Technologies, Inc. in the Global Next-Generation
Gynecological Cancer Diagnostics Market .............................................146
15.2.3 Key Customers of the Company ..............................................................146
15.2.4 Key Competitors of the Company............................................................147
15.2.5 Financials...................................................................................................148
15.2.6 Key Insights About Financial Health of the Company ...........................150
15.2.7 Business Strategies ..................................................................................150
8. 8
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
15.2.8 SWOT Analysis..........................................................................................151
15.3 ARUP Laboratories........................................................................................152
15.3.1 Company Overview ...................................................................................152
15.3.2 Role of ARUP Laboratories in the Global Next-generation
gynecological Cancer Diagnostics Market..............................................152
15.3.3 Key Customers of the Company ..............................................................152
15.3.4 Key Competitors of the Company............................................................153
15.3.5 SWOT Analysis..........................................................................................154
15.4 BGI Genomics................................................................................................155
15.4.1 Company Overview ...................................................................................155
15.4.2 Role of BGI Genomics in the Global Next-Generation Gynecological
Cancer Diagnostics Market ......................................................................155
15.4.3 Key Customers of the Company ..............................................................155
15.4.4 Key Competitors of the Company............................................................156
15.4.5 Business Strategies ..................................................................................156
15.4.6 SWOT Analysis..........................................................................................157
15.5 CENTOGENE N.V...........................................................................................158
15.5.1 Company Overview ...................................................................................158
15.5.2 Role of CENTOGENE N.V. in the Global Next-Generation
Gynecological Cancer Diagnostics Market .............................................158
15.5.3 Key Customers of the Company ..............................................................158
15.5.4 Key Competitors of the Company............................................................159
15.5.5 Financials...................................................................................................160
15.5.6 Key Insights About Financial Health of the Company ...........................162
15.5.7 SWOT Analysis..........................................................................................163
15.6 F. Hoffmann-La Roche Ltd............................................................................164
15.6.1 Company Overview ...................................................................................164
15.6.2 Role of F. Hoffmann-La Roche Ltd in the Global Next-Generation
Gynecological Cancer Diagnostics Market .............................................164
15.6.3 Key Customers of the Company ..............................................................164
15.6.4 Key Competitors of the Company............................................................165
9. 9
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
15.6.5 Financials...................................................................................................166
15.6.6 Key Insights About Financial Health of the Company ...........................168
15.6.7 Business Strategies ..................................................................................168
15.6.8 SWOT Analysis..........................................................................................169
15.7 Fulgent Genetics, Inc. ...................................................................................170
15.7.1 Company Overview ...................................................................................170
15.7.2 Key Customers of the Company ..............................................................170
15.7.3 Key Competitors of the Company............................................................171
15.7.4 Financials...................................................................................................172
15.7.5 Key Insights About Financial Health of the Company ...........................173
15.7.6 Business Strategies ..................................................................................173
15.7.7 SWOT Analysis..........................................................................................174
15.8 Illumina, Inc....................................................................................................175
15.8.1 Company Overview ...................................................................................175
15.8.2 Role of Illumina, Inc. in the Global Next-Generation Gynecological
Cancer Diagnostics Market ......................................................................175
15.8.3 Key Customers of the Company ..............................................................175
15.8.4 Key Competitors of the Company............................................................176
15.8.5 Financials...................................................................................................177
15.8.6 Key Insights About Financial Health of the Company ...........................179
15.8.7 SWOT Analysis..........................................................................................180
15.9 Invitae Corporation........................................................................................181
15.9.1 Company Overview ...................................................................................181
15.9.2 Role of Invitae Corporation in the Global Next-Generation
Gynecological Cancer Diagnostics Market .............................................181
15.9.3 Key Customers of the Company ..............................................................181
15.9.4 Key Competitors of the Company............................................................182
15.9.5 Financials...................................................................................................183
15.9.6 Key Insights About Financial Health of the Company ...........................185
15.9.7 Business Strategies ..................................................................................185
10. 10
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
15.9.8 SWOT Analysis..........................................................................................186
15.10 Konica Minolta, Inc........................................................................................187
15.10.1 Company Overview.............................................................................187
15.10.2 Role of Konica Minolta, Inc. in the Global Next-Generation
Gynecological Cancer Diagnostics Market .............................................187
15.10.3 Key Customers of the Company........................................................187
15.10.4 Key Competitors of the Company .....................................................188
15.10.5 Financials ............................................................................................189
15.10.6 Key Insights About Financial Health of the Company.....................191
15.10.7 Business Strategies............................................................................191
15.10.8 SWOT Analysis....................................................................................192
15.11 Laboratory Corporation of America Holdings.............................................193
15.11.1 Company Overview.............................................................................193
15.11.2 Role of Laboratory Corporation of America Holdings in the
Global Next-Generation Gynecological Cancer Diagnostics Market ....193
15.11.3 Key Customers of the Company........................................................193
15.11.4 Key Competitors of the Company .....................................................194
15.11.5 Financials ............................................................................................195
15.11.6 Business Strategies............................................................................196
15.11.7 SWOT Analysis....................................................................................197
15.12 Myriad Genetics, Inc......................................................................................198
15.12.1 Company Overview.............................................................................198
15.12.2 Role of Myriad Genetics, Inc. in the Global Next-Generation
Gynecological Cancer Diagnostics Market .............................................198
15.12.3 Key Customers of the Company........................................................198
15.12.4 Key Competitors of the Company .....................................................199
15.12.5 Financials ............................................................................................200
15.12.6 SWOT Analysis....................................................................................201
15.13 OPKO Health, Inc...........................................................................................202
15.13.1 Company Overview.............................................................................202
11. 11
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
15.13.2 Role of OPKO Health, Inc. in the Global Next-Generation
Gynecological Cancer Diagnostics Market .............................................202
15.13.3 Key Customers of the Company........................................................202
15.13.4 Key Competitors of the Company .....................................................203
15.13.5 Financials ............................................................................................204
15.13.6 Key Insights About Financial Health of the Company.....................206
15.13.7 SWOT Analysis....................................................................................207
15.14 QIAGEN N.V....................................................................................................208
15.14.1 Company Overview.............................................................................208
15.14.2 Role of QIAGEN N.V. in the Global Next-Generation
Gynecological Cancer Diagnostics Market .............................................208
15.14.3 Key Customers of the Company........................................................208
15.14.4 Key Competitors of the Company .....................................................209
15.14.5 Financials ............................................................................................210
15.14.6 Key Insights About Financial Health of the Company.....................212
15.14.7 Business Strategies............................................................................212
15.14.8 SWOT Analysis....................................................................................213
15.15 Quest Diagnostics Incorporated ..................................................................214
15.15.1 Company Overview.............................................................................214
15.15.2 Role of Quest Diagnostics Incorporated in the Global Next-
Generation Gynecological Cancer Diagnostics Market .........................214
15.15.3 Key Customers of the Company........................................................214
15.15.4 Key Competitors of the Company .....................................................215
15.15.5 Financials ............................................................................................216
15.15.6 SWOT Analysis....................................................................................217
15.16 Thermo Fisher Scientific Inc.........................................................................218
15.16.1 Company Overview.............................................................................218
15.16.2 Role of Thermo Fisher Scientific Inc. in the Global Next-
Generation Gynecological Cancer Diagnostics Market .........................218
15.16.3 Key Customers of the Company........................................................218
15.16.4 Key Competitors of the Company .....................................................219
12. 12
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
15.16.5 Financials ............................................................................................220
15.16.6 Key Insights About Financial Health of the Company.....................222
15.16.7 SWOT Analysis....................................................................................223
Emerging companies .................................................................... 224
15.17 Overview.........................................................................................................224
15.18 NgeneBio........................................................................................................224
15.18.1 Company Overview.............................................................................224
15.18.2 Role of NgeneBio in the Global Next-Generation Gynecological
Cancer Diagnostics Market ......................................................................224
15.19 oncgnostics GmbH........................................................................................225
15.19.1 Company Overview.............................................................................225
15.19.2 Role of oncgnostics GmbH in the Global Next-Generation
Gynecological Cancer Diagnostics Market .............................................225
15.20 Self-screen B.V. .............................................................................................226
15.20.1 Company Overview.............................................................................226
15.20.2 Role of Self-screen B.V. in the Global Next-Generation
Gynecological Cancer Diagnostics Market .............................................226
15.21 Strata Oncology, Inc......................................................................................227
15.21.1 Company Overview.............................................................................227
15.21.2 Role of Strata Oncology, Inc. in the Global Next-Generation
Gynecological Cancer Diagnostics Market .............................................227
13. 13
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
List of Figures
Figure 1: Impact Analysis of Market Drivers and Opportunities in Global Next-Generation Gynecological
Cancer Diagnostics Market
Figure 2: Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), 2020 and
2031
Figure 3: Global Next-Generation Gynecological Cancer Diagnostics Market (by Product Type), 2020
and 2031
Figure 4: Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), 2020 and
2031
Figure 5: Global Next-Generation Gynecological Cancer Diagnostics Market (by End User), 2020 and
2031
Figure 6: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), 2020-2031
Figure 7: Global Next-Generation Gynecological Cancer Diagnostics Market Segmentation
Figure 8: Figure: Global Next-Generation Gynecological Cancer Diagnostics Market: Methodology
Figure 9: Figure: Bottom-Up Approach (Segment-Wise Analysis)
Figure 10: Figure: Top-Down Approach (Segment-Wise Analysis)
Figure 11: Cervical Cancer, Incidence Cases and New Cases (2008-2018)
Figure 12: Ovarian Cancer, Incidence Cases and New Cases (2008-2018)
Figure 13: Molecular Diagnostics Evolution Timeline
Figure 14: Types of Molecular Diagnostics Technologies
Figure 15: Diagnostic Technologies and Regulatory Landmark Timeline
Figure 16: Type of Non-Invasive Next Generation Novel Molecular Diagnostics
Figure 17: Evolution of Sequencing Technologies
Figure 18: Difference Between Polymerase Chain reaction (PCR) Across Three Generation Sequencing
Figure 19: Global Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 20: Potential Biomarkers for Gynecological Cancer Detection
Figure 21: Number of Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx),
(1998–2020)
Figure 22: Number of Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx)
Assays by Analytical Platform/Technology
Figure 23: Laboratory Setting and Testing Methodologies Being Adopted by the Respondent’s
Laboratories
Figure 24: Types of Molecular Testing for Cancer Performed
14. 14
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 25: Global Next-Generation Gynecological Cancer Diagnostics Market: COVID-19 Impact
Figure 26: Impact of COVID-19 on Global Next-Generation Gynecological Cancer Diagnostics Market
Figure 27: Global Next-Generation Gynecological Cancer Diagnostics, Market Dynamics
Figure 28: Impact Analysis of Market Drivers and Opportunities on Global Next-Generation
Gynecological Cancer Diagnostics Market
Figure 29: Cost per Human Genome (2014–2021)
Figure 30: Approved Number of Personalized Medicine (2016–2020)
Figure 31: Percentage of Food and Drug Administration (FDA) Approved Personalized Medicines (2015–
2020)
Figure 32: Next-Generation Sequencing (NGS) for Human Papillomavirus (HPV) Detection and
Characterization Process Steps
Figure 33: Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), 2020 and
2031
Figure 34: Global Next-Generation Gynecological Cancer Diagnostics Market (Polymerase Chain
Reaction (PCR)), $Million, 2020-2031
Figure 35: Global Next-Generation Gynecological Cancer Diagnostics Market (Polymerase Chain
Reaction (PCR)), Thousand Units, 2020-2031
Figure 36: Global Next-Generation Gynecological Cancer Diagnostics Market (Next-Generation
Sequencing (NGS)), $Million, 2020-2031
Figure 37: Global Next-Generation Gynecological Cancer Diagnostics Market (Next-Generation
Sequencing (NGS)), Thousand Units, 2020-2031
Figure 38: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation
Sequencing (NGS), Broad Panels), $Million, 2020-2031
Figure 39: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation
Sequencing (NGS), Broad Panels), Thousand Units, 2020-2031
Figure 40: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation
Sequencing (NGS), Targeted Gene Panels), $Million, 2020-2031
Figure 41: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation
Sequencing (NGS), Targeted Gene Panels), Thousand Units, 2020-2031
Figure 42: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation
Sequencing (NGS), Single Gene Panels), $Million, 2020-2031
Figure 43: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation
Sequencing (NGS), Single Gene Panels), Thousand Units, 2020-2031
Figure 44: Global Next-Generation Gynecological Cancer Diagnostics Market (Other Technologies),
$Million, 2020-2031
15. 15
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 45: Global Next-Generation Gynecological Cancer Diagnostics Market (Other Technologies),
Thousand Units, 2020-2031
Figure 46: Global Next-Generation Gynecological Cancer Diagnostics Market (by Product Type), 2020
and 2031
Figure 47: Global Next-Generation Gynecological Cancer Diagnostics Market (Services), $Million, 2020-
2031
Figure 48: Global Next-Generation Gynecological Cancer Diagnostics Market (Products), $Million, 2020-
2031
Figure 49: Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), 2020 and
2031
Figure 50: Global Next-Generation Gynecological Cancer Diagnostics Market (Ovarian Cancer), $Million,
2020-2031
Figure 51: Global Next-Generation Gynecological Cancer Diagnostics Market (Cervical Cancer), $Million,
2020-2031
Figure 52: Global Next-Generation Gynecological Cancer Diagnostics Market (Uterine Cancer), $Million,
2020-2031
Figure 53: Global Next-Generation Gynecological Cancer Diagnostics Market (by End User), 2020 and
2031
Figure 54: Global Next-Generation Gynecological Cancer Diagnostics Market (Academic and Research
Institutes), $Million, 2020-2031
Figure 55: Global Next-Generation Gynecological Cancer Diagnostics Market (Hospitals and Ambulatory
Centers), $Million, 2020-2031
Figure 56: Global Next-Generation Gynecological Cancer Diagnostics Market (Diagnostic Laboratories),
$Million, 2020-2031
Figure 57: Global Next-Generation Gynecological Cancer Diagnostics Market (Other End Users),
$Million, 2020-2031
Figure 58: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region)
Figure 59: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), 2020-2031
Figure 60: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), $Million,
2020-2031
Figure 61: North America Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-
2031
Figure 62: North America, Market Dynamics
Figure 63: North America Next-Generation Gynecological Cancer Diagnostics Market (by Country),
2020-2031
16. 16
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 64: U.S. Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 65: Canada Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 66: Europe Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 67: Europe, Market Dynamics
Figure 68: Europe Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020-2031
Figure 69: Germany Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 70: U.K. Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 71: France Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 72: Italy Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 73: Spain Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 74: Netherlands Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 75: Rest-of-Europe Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-
2031
Figure 76: Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 77: APAC, Market Dynamics
Figure 78: APAC Next-Generation Gynecological Market (by Country), 2020-2031
Figure 79: China Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 80: Japan Next-Generation Cancer Gynecological Cancer Diagnostics Market, $Million, 2020-
2031
Figure 81: India Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 82: Australia Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 83: South Korea Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 84: RoAPAC Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 85: Latin America Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-
2031
Figure 86: Latin America, Market Dynamics
Figure 87: Latin America Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020-
2031
Figure 88: Brazil Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 89: Mexico Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 90: Rest-of-Latin America Next-Generation Gynecological Cancer Diagnostics Market, $Million,
2020-2031
Figure 91: RoW Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
17. 17
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 92: Share of Key Developments and Strategies, January 2019–January 2022
Figure 93: Share of Regulatory and Legal Activities (by Company), January 2019–January 2022
Figure 94: Share of Synergistic Activities (by Company), January 2019–January 2022
Figure 95: Share of Mergers and Acquisitions (by Company), January 2019–January 2022
Figure 96: Share of Product Launches (by Company), January 2019–January 2022
Figure 97: Share of Business Expansions (by Company), January 2019–January 2022
Figure 98: Market Share Analysis for Global Next-Generation Gynecological Cancer Diagnostics Market
(by Service Providers), 2020
Figure 99: Market Share Analysis for Global Next-Generation Gynecological Cancer Diagnostics Market
(by Manufacturers), 2020
Figure 100: Growth Share Analysis for Global next-generation gynecological cancer diagnostics, (by
Service Providers), 2020
Figure 101: Growth Share Analysis for Global next-generation gynecological cancer diagnostics, (by
Product Manufacturers), 2020
Figure 102: Shares of Key Company Profiles
Figure 103: Agilent Technologies, Inc.: Product Portfolio
Figure 104: Agilent Technologies, Inc.: Overall Financials/Revenue, $Million, 2019-2021
Figure 105: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 106: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 107: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 108: Agilent Technologies, Inc.: SWOT Analysis
Figure 109: ARUP Laboratories: Service Portfolio
Figure 110: ARUP Laboratories: SWOT Analysis
Figure 111: BGI Genomics: Product Portfolio
Figure 112: BGI Genomics: SWOT Analysis
Figure 113: CENTOGENE N.V.: Service Portfolio
Figure 114: CENTOGENE N.V.: Overall Financials/Revenue, $Million, 2018-2020
Figure 115: CENTOGENE N.V.: Revenue (by Business Segment), $Million, 2018-2020
Figure 116: CENTOGENE N.V.: Revenue (by Region), $Million, 2018-2020
Figure 117: CENTOGENE N.V.: R&D Expenditure, $Million, 2018-2020
Figure 118: CENTOGENE N.V.: SWOT Analysis
Figure 119: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 120: F. Hoffmann-La Roche Ltd: Overall Financials/Revenue, $Billion, 2019-2021
18. 18
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 121: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Billion, 2019-2021
Figure 122: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Billion, 2019-2021
Figure 123: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Billion, 2019-2021
Figure 124: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 125: Fulgent Genetics, Inc.: Service Portfolio
Figure 126: Fulgent Genetics, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 127: Fulgent Genetics, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 128: Fulgent Genetics, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 129: Fulgent Genetics, Inc.: SWOT Analysis
Figure 130: Illumina, Inc.: Product Portfolio
Figure 131: Illumina, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 132: Illumina, Inc.: Revenue (by Business Segment), $Million, 2018–2020
Figure 133: Illumina, Inc.: Revenue (by Region), $Million, 2018–2020
Figure 134: Illumina, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 135: Illumina, Inc.: SWOT Analysis
Figure 136: Invitae Corporation: Service Portfolio
Figure 137: Invitae Corporation: Overall Financials/Revenue, $Million, 2018-2020
Figure 138: Invitae Corporation: Revenue (by Business Segment), $Million, 2018–2020
Figure 139: Invitae Corporation: Revenue (by Region), $Million, 2018-2020
Figure 140: Invitae Corporation: R&D Expenditure, $Million, 2018-2020
Figure 141: Invitae Corporation: SWOT Analysis
Figure 142: Konica Minolta, Inc.: Service Portfolio
Figure 143: Konica Minolta, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 144: Konica Minolta, Inc.: Revenue (by Business Segment), $Million, 2019-2020
Figure 145: Konica Minolta, Inc.: Revenue (by Healthcare Business), $Million, 2019-2020
Figure 146: Konica Minolta, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 147: Konica Minolta, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 148: Konica Minolta, Inc.: SWOT Analysis
Figure 149: Laboratory Corporation of America Holdings: Service Portfolio
Figure 150: Laboratory Corporation of America Holdings: Overall Financials/Revenue, $Million, 2018-2020
Figure 151: Laboratory Corporation of America Holdings: Revenue (by Segment), $Million, 2018-2020
Figure 152: Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2018-2020
Figure 153: Laboratory Corporation of America Holdings: SWOT Analysis
19. 19
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 154: Myriad Genetics, Inc.: Service Portfolio
Figure 155: Myriad Genetics, Inc.: Overall Financials/Revenue, 2018-2020
Figure 156: Myriad Genetics, Inc.: Revenue (by Business Segment), 2018-2020
Figure 157: Myriad Genetics, Inc.: SWOT Analysis
Figure 158: OPKO Health, Inc.: Service Portfolio
Figure 159: OPKO Health, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 160: OPKO Health, Inc.: Revenue (by Business Segment), $Million, 2018–2020
Figure 161: OPKO Health, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 162: OPKO Health, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 163: OPKO Health: SWOT Analysis
Figure 164: QIAGEN N.V.: Product Portfolio
Figure 165: QIAGEN N.V.: Overall Financials/Revenue, 2019-2021
Figure 166: QIAGEN N.V.: Revenue (by Segment), 2019-2021
Figure 167: QIAGEN N.V.: Revenue (by Region), 2019-2021
Figure 168: QIAGEN N.V.: R&D Expenditure, 2019-2021
Figure 169: QIAGEN N.V.: SWOT Analysis
Figure 170: Quest Diagnostics Incorporated: Service Portfolio
Figure 171: Quest Diagnostics Incorporated: Overall Financials/Revenue, $Million, 2018-2020
Figure 172: Quest Diagnostics Incorporated: Revenue (by Business Segment), $Million, 2018-2020
Figure 173: Quest Diagnostics Incorporated: SWOT Analysis
Figure 174: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 175: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2018-2020
Figure 176: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2018–2020
Figure 177: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2018–2020
Figure 178: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2018-2020
Figure 179: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 180: NgeneBio: Product Portfolio
Figure 181: oncgnostics GmbH: Product Portfolio
Figure 182: Self-screen B.V.: Product Portfolio
Figure 183: Strata Oncology, Inc.: Product Portfolio
20. 20
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
List of Tables
Table 1: Risks Associated with the Types of Genes Related to Hereditary Ovarian and Uterine Cancer
Table 2: Advantages and Limitations of Short-Read Sequencing and Long-Read Sequencing
Table 3: National Comprehensive Cancer Network (NCCN) Recommended Predictive Molecular
Testing in Gynecological Cancer
Table 4: Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx) for
Gynecological Cancers
Table 5: Reimbursement Scenario Across Major Countries
Table 6: Regulatory Framework and Reimbursement Options of NGS-Based Diagnostics Across Major
Countries
Table 7: Next-Generation Sequencing Clinical Utility in Gynecological Cancers
Table 8: Services Offered by Key Players
Table 9: Products Offered by Key Players
21. 21
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More
22. 22
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties, and contingencies
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135
23. 23
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com